Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry

Autor: Belli, LS, Perricone, G, Adam, R, Cortesi, PA, Strazzabosco, M, Facchetti, R, Karam, V, Salizzoni, M, Andujar, RL, Fondevila, C, De Simone, P, Morelli, C, Fabregat-Prous, J, Samuel, D, Agarwaal, K, Gonzales, EM, Charco, R, Zieniewicz, K, De Carlis, L, Duvoux, C, ELITA
Rok vydání: 2018
Předmět:
Zdroj: JOURNAL OF HEPATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ISSN: 0168-8278
Popis: Background & Aims: Direct-acting antivirals (DAAs) have dramatically improved the outcome of patients with hepatitis C virus (HCV) infection including those with decompensated cirrhosis (DC). We analyzed the evolution of indications and results of liver transplantation (LT) in the past 10 years in Europe, focusing on the changes induced by the advent of DAAs. Methods: This is a cohort study based on data from the European Liver Transplant Registry (ELTR). Data of adult LTs performed between January 2007 to June 2017 for HCV, hepatitis B virus (HBV), alcohol (EtOH) and non-alcoholic steatohepatitis (NASH) were analyzed. The period was divided into different eras: interferon (IFN/RBV; 2007-2010), protease inhibitor (PI; 2011-2013) and second generation DAA (DAA; 2014-June 2017). Results: Out of a total number of 60,527 LTs, 36,382 were performed in patients with HCV, HBV, EtOH and NASH. The percentage of LTs due to HCV-related liver disease varied significantly over time (p
Databáze: OpenAIRE
Externí odkaz: